News Release：2024 | Eisai Co., Ltd.
Oct 30, 2024 · eisai completes a major renovation of tsukuba research laboratories as a global drug discovery center aiming for connecting human and human, and data, and the world. april 4, 2023. eisai publishes long-term health outcomes using simulation model of lecanemab using phase 3 clarity ad data in peer-reviewed neurology and therapy journal
FDA Approves LEQEMBI™ (lecanemab-irmb) Under the ... - Eisai …
Jan 7, 2023 · FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer’s Disease. Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI™. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment ...
EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 …
Nov 30, 2022 · Design of Clarity AD Study. Eisai’s Clarity AD was a global confirmatory Phase 3 placebo-controlled, double-blind, parallel-group, randomized study in 1,795 people with early AD (lecanemab group: 898 placebo group: 897) at 235 sites in North America, Europe, and Asia.
LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET
Sep 28, 2022 · eisai's news release lecanemab confirmatory phase 3 clarity ad study met primary endpoint, showing highly statistically significant reduction of clinical decline in large global clinical study of 1,795 participants with early alzheimer’s disease is posted.
News Release：2021 | Eisai Co., Ltd.
Dec 16, 2021 · November 30, 2021. EISAI TO PRESENT LATEST DATA ON PERAMPANEL AND E2730 AT THE 75TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING. November 29, 2021. European Commission Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) for Patients With Certain Types of Endometrial Carcinoma.
New Clinical Data Demonstrates Three Years of ... - Eisai Co., Ltd.
Jul 31, 2024 · More than 50% of Patients Who Started Treatment in the Earliest Stage of AD Continued to Show Improvement After Three Years of Lecanemab Treatment. The Clarity AD study included an optional tau PET substudy and used the tau PET probe MK6240 to identify patients with no tau or a low accumulation of tau in the brain.
EISAI ANNOUNCES MOVE TO SOLO DEVELOPMENT AND …
Jul 1, 2024 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug ...
Notification of Ransomware Incident | News Release：2023 - Eisai …
Jun 6, 2023 · A ransomware incident that encrypted some of Eisai Group’s servers was detected late night on Saturday, June 3, Japan time. We immediately implemented our incident response plan and launched an investigation with the aid of our cybersecurity partners.
EISAI AND BIOGEN INC. ANNOUNCE U.S. FDA GRANTS ... - Eisai …
Jun 24, 2021 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, “Biogen”) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lecanemab (BAN2401), an investigational anti ...
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker ...
Jul 20, 2023 · LEQEMBI is an amyloid beta-directed antibody indicated as a disease-modifying treatment for Alzheimer’s disease (AD) in the U.S. The U.S. Food and Drug Administration (FDA) granted LEQEMBI accelerated approval on January 6, …